Chronic lymphocytic leukemia in Turkey:: Experience of a single center in Istanbul

被引:9
|
作者
Pamuk, ON
Pamuk, GE
Soysal, T
Öngören, N
Baslar, ZB
Ferhanoglu, B
Aydin, Y
Ülkü, B
Aktuglu, G
Akman, N
机构
[1] Istanbul Univ, Cerrahpasa Med Fac, Dept Internal Med, Div Hematol, Istanbul, Turkey
[2] Trakya Univ, Fac Med, Edirne, Turkey
关键词
chronic lymphocytic leukemia; survival; prognosis; Rai's classification; Binet's classification;
D O I
10.1097/01.SMJ.0000053674.03385.B7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In this study, the clinical characteristics, survival, and prognostic factors of 200 patients diagnosed as having chronic lymphocytic leukemia (CLL) were analyzed. Methods: The medical charts of 200 CLL patients registered to our center between 1984 and 2000 were retrospectively evaluated. stage patients, was shorter than that in other CLL series of Western origin. Rai's staging system was seen to determine prognosis better than Binet's staging system. Results: Of all patients, 129 were men and 71 were women (male/female ratio, 1.82). The median age at the time of initial diagnosis was 63 years (range, 38-90 years). Sixty patients were classified as Binet's Stage A, 49 as Stage B, and 91 as Stage C. Sixty-two cases were diagnosed during routine laboratory examinations when they were asymptomatic. Forty-three patients were lost to follow-up, and 157 patients have been followed regularly until the end of the study period. Hemolytic anemia developed in nine (5.7%) patients, second primary cancer in six (3.8%), and Richter's syndrome in two (1.2%). Forty-eight percent of CLL patients were treated immediately after initial diagnosis. The overall response (complete or partial) to first-line and second-line therapies was 61.6% and 54.4%, respectively. The median time of follow-up for patients followed up regularly was 47 months (range, 1-195 months). Sixty-three patients died during the follow-up: the deaths of 39 (62%) of these were attributable to CLL-related causes. The median survival time was 48 months. The 5-year survival rate was 36.5% and the 10-year survival rate was 8%. Stage according to Rai's classification, lymphocyte count, and age showed a significant prognostic effect on survival by univariate analysis. On multivariate analysis, advanced age and lymphocyte count were independent prognostic parameters. Conclusion: In our study, more asymptomatic CLL patients have been diagnosed in recent years. The survival, especially of our early-stage patients, was shorter than that in other CLL series of Western origin. Rai's staging system was seen to determine prognosis better than Binet's staging system.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 50 条
  • [1] Chronic Lymphocytic Leukemia Treatment: Single Center Experience
    Alshemmari, Salem Salem
    Al-sarraf, Ahmed
    Kunhikrishnan, Anita
    Alhuraiji, Ahmad
    Hamadah, Abdulaziz
    BLOOD, 2022, 140 : 12416 - 12417
  • [2] Ibrutinib for Chronic Lymphocytic Leukemia (CLL): A Single Center Experience in Bogota, Colombia
    Bohorquez, Leonardo
    Abello, Virginia
    Helena Solano, Maria
    Casas, Claudia
    Espinosa, Daniel
    Leon, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S285 - S285
  • [3] Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients
    Briani, Chiara
    Visentin, Andrea
    Salvalaggio, Alessandro
    Imbergamo, Silvia
    Piazza, Francesco
    Cacciavillani, Mario
    Campagnolo, Marta
    Frezzato, Federica
    Semenzato, Gianpietro
    Trentin, Livio
    HAEMATOLOGICA, 2017, 102 (04) : E140 - E143
  • [4] THE CLINICAL FEATURES OF 105 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FOLLOWED UP AT A SINGLE CENTER IN TURKEY
    Pamuk, G.
    Uyanik, M.
    Akker, M.
    Demir, M.
    HAEMATOLOGICA, 2012, 97 : 529 - 530
  • [5] PERIPHERAL NEUROPATHY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SINGLE CENTER EXPERIENCE ON 795 PATIENTS
    Briani, C.
    Visentin, A.
    Salvalaggio, A.
    Imbergamo, S.
    Zambello, R.
    Cacciavillani, M.
    Campagnolo, M.
    Semenzato, G.
    Trentin, L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 : S5 - S6
  • [6] Treatment strategies and outcomes for double refractory chronic lymphocytic leukemia; a single center experience
    Din, Mohammad Ammad Ud
    Knepper, Todd
    Chavez, Julio
    Nodzon, Lisa
    Gaballah, Sameh
    Saeed, Hayder
    Sokol, Lobomir
    Dong, Ning
    Isenalumhe, Leidy
    Bello, Celeste
    Shah, Bijal
    Pinilla-Ibarz, Javier
    LEUKEMIA & LYMPHOMA, 2023, 64 : S72 - S74
  • [7] Use of Bendamustine Combined with Rituximab in Chronic Lymphocytic Leukemia Patients: A Single Center Experience
    Ozmen, Deniz
    Keskin, Dilek
    Yurttas, Nurgul Ozgur
    Sadri, Sevil
    Salihoglu, Ayse
    Eskazan, Ahmet Emre
    Ar, M. Cem
    Ongoren, Seniz
    Baslar, Zafer
    Soysal, Teoman
    BLOOD, 2017, 130
  • [8] COVID-19 in Children: A Single Center Experience from Istanbul, Turkey
    Besli, Gulser Esen
    Demir, Sevliya Ocal
    Girit, Saniye
    Arman, Tugce
    Duyu, Muhterem
    Arslanoglu, Sertac
    MEDICAL JOURNAL OF BAKIRKOY, 2021, 17 (01) : 64 - 71
  • [9] The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience
    Sevinc, Mustafa
    Karabulut, Aydin
    Eskazan, Ahmet Emre
    Tatonyan, Suzin Catal
    Ozbek, Ugur
    Soysal, Teoman
    LABORATORY MEDICINE, 2020, 51 (03) : 259 - 264
  • [10] EXPERIENCE IN OUR CENTER WITH THE USE OF RITUXIMAB - VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Pimentel, Villar Ma
    De Leon, Marcano E.
    Jimenez, Moreno M.
    Lopez, Marquez T. J.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2020, 105 : 389 - 390